MMF induction is a viable alternative to cyclophosphamide for treating mixed proliferative lupus nephritis in children. Oral mycophenolate mofetil (MMF) is as effective as intravenous cyclophosphamide ...

In children with lupus nephritis, neurological manifestations at the time of kidney biopsy, age, and eGFR predicted greater risk of CKD progression. Investigators have identified predictors of chronic ...

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. GSK plc (LSE/NYSE: GSK) today ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

The decision is based on outcomes from the Phase II NOBILITY and Phase III REGENCY trials.

Please provide your email address to receive an email when new articles are posted on . Lupus nephritis is a common complication of systemic lupus erythematosus. New therapies are now available with ...

Please provide your email address to receive an email when new articles are posted on . Data from Spherix Global Insights show increasing comfort with obinutuzumab in lupus nephritis treatment.

Background Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells but typically regarded as ...

Basel: Roche has announced that the European Commission has approved Gazyva/Gazyvaro (obinutuzumab) in combination with ...

Gazyva/Gazyvaro is approved for adults with lupus nephritis in the United States and European Union and in over 100 countries for various types of haematological cancers.